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1  | INTRODUC TION
Feeding Atlantic salmon diets with high inclusion of plant ingredi‐
ents, low in nutrients naturally present in animal ingredients, results 
in a more obese salmon with increased visceral and plasma TAG 
(Torstensen, Espe, Stubhaug, & Lie, 2011). Likewise, undernutrition 
of methionine increased visceral mass (Espe, Hevrøy, Liaset, Lemme, 
& El‐Mowafi, 2008) and liver TAG accumulation (Espe, Rathore, Du, 
Liaset, & El‐Mowafi, 2010). These findings indicated that amino 
acid‐imbalanced diets increase adiposity in fish. In humans, obesity 
is associated with non‐alcoholic fatty liver disease (NAFLD) in com‐
bination with insulin resistance, high plasma glucose concentrations 
and increased plasma circulating lipids. Increased liver TAG is widely 
accepted as the onset of NAFLD, and this is strongly associated with 
central obesity and insulin resistance in humans (Cohen, Horton, & 
Hobbs, 2011). In addition, methionine choline deficiency (Chawla 
et al., 1998; Slow & Garrow, 2006) or high‐cysteine diets concomi‐
tantly containing low dietary methionine and choline result in liver 
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Abstract
The following study aimed to develop a fatty liver model in primary hepatocytes 
isolated from Atlantic salmon. In order to induce the fatty liver, oleic acid (OA) at 0.2 
or 0.4 mM was used. Metformin, known to prevent and cure fatty liver in mammalian 
cells, was used at 1 or 10 mM for 24 hr before addition of OA to test possible preven‐
tion effect of metformin on the OA‐induced fatty liver phenotype. Cells grown in 
0.2 mM OA did not increase the mean number of lipid droplets, while cells grown in 
0.4 mM OA increased the number of lipid droplets within the liver cells (p < 0.0001). 
Metformin pretreatment prior to OA supplementation reduced the mean number of 
lipid droplets. Gene expression of ApoB100, CD36 and PPARa increased in cells 
treated with metformin and most so at 10 mM. On the other hand, gene expression 
of LXR, SREBP2 and CPT‐1 decreased at both concentrations of metformin, while OA 
treatment did not affect these genes. Gene expression of IL‐8 increased by 0.4 mM 
OA (p = 0.002). Metformin reduced the gene expression of IL‐8. Thus, metformin ef‐
ficiently enhanced the expression of genes related to transport and oxidation of lipids 
in hepatic cells of salmon, but required higher concentrations of OA and metformin 
than those required in rodent models to increase and prevent lipid accumulation, 
respectively.
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TAG accumulation in rodents (Toohey, 2014). Treatment with oleic 
acid (OA) is a well‐recognized method for experimentally promoting 
the development of fatty liver in rodent models (Lian et al., 2011; 
Vidyashankar, Varma, & Patki, 2013). Whether TAG accumulation 
present in salmon liver is similar to NAFLD described in both rodent 
and human models is not known. Although obesity seems closely re‐
lated to the presence and balance of amino acids, including sulphur 
amino acids, within tissue compartments in salmon (Espe et al., 2010; 
Torstensen et al., 2011), details in its signalling molecules and energy 
regulation promoting TAG accumulation in salmon are still largely un‐
known. Recently, Zhou et al. (2019) reported that high‐fat‐fed liver 
cells had increased TAG and cholesterol as compared to low‐fat‐fed 
cells. Further, cells treated with metformin upregulated AMP‐acti‐
vated protein kinase (AMPK) and had a higher expression of genes 
associated with lipid metabolism.
Metformin has been used to treat diabetes 2 during the past 
50 years (He et al., 2009) as it increases plasma glucose clearance 
(Mazza et al., 2012) and reduces glucose production (Cao et al., 2014). 
Metformin reduced TAG accumulation in diet‐induced fatty liver 
model in rodent (Liu et al., 2014). The reduction in lipid accumulation 
probably occurs through sensing of energy status as metformin phos‐
phorylates and activates AMPK, the main regulator of energy sensing 
inside cells (Viollet et al., 2012). Further, metformin administration 
reduced body weight and obesity in humans. However, the mecha‐
nisms behind this weight reduction are not fully understood (Malin 
& Kashyap, 2014). Additionally metformin administration is reported 
to reduce endoplasmatic reticulum stress (Simon‐Szabó, Kokas, 
Mandi, Keri, & Csala, 2014) which is often associated with increased 
inflammation and lack of appropriate antioxidative compounds 
(Esser, Legrand‐Poels, Piette, Scheen, & Paquot, 2014; Matsunada 
& Shimomura, 2013; Pitocco, Tesauro, Allesandro, Ghirlanda, & 
Cardillo, 2013; Vonghia, Michielsen, & Francque, 2013). Panserat et 
al. (2009) reported that rainbow trout fed high‐carbohydrate diets re‐
duced hyperglycaemia following metformin treatment and had higher 
activities of lipogenic enzymes. Nutrients’ ability to prevent TAG ac‐
cumulation is of high interest in fish nutrition, while treatment of TAG 
accumulation is of lower interest. The following experiments aimed 
at developing a model for TAG accumulation using primary liver 
cells isolated from Atlantic salmon using OA, furthermore, to assess 
whether metformin might have the ability to prevent the OA‐induced 
TAG accumulation in these cells, thus making the model suitable to 
be used in studies evaluating effect of nutrient supply on changes 
leading to liver TAG accumulation.
2  | MATERIAL S AND METHODS
2.1 | Isolation of primary liver cells
The aquarium in Bergen housed the Atlantic salmon used in the cur‐
rent study. The fish were fed the same commercial feed. Primary 
liver cells were isolated from Atlantic salmon as described elsewhere 
(Espe & Holen, 2013). In brief, primary liver cells were isolated from 
Atlantic salmon with an average BW of 512 ± 75 g (two males and 
three females). The liver was perfused with 0.09 M HEPES buffer 
containing 1.4 M NaCl, 0.067 M KCl and 0.03 M EDTA (pH 7.4) 
until free from blood; thereafter, livers were digested with colla‐
genase (0.1% dissolved in the HEPES buffer). Cells were squeezed 
through a Falcon cell strainer, and the isolated cells were dissolved 
in Leibovitz‐15 (L‐15) media and washed three times in L‐15 media. 
Cell viability and counting were done using Trypan blue (Lonzo, 
MedProbe). Before handling, fish were anaesthetized with meta‐
caine (MS222, 5–8 g/L) and killed with a blow to the head before 
liver cells were isolated. The Norwegian Board of Experiments with 
Living Animals approved the protocol applied.
2.2 | Cell studies
The isolated primary liver cells were plated in laminin‐coated 6‐well 
plates at a concentration of 0.8 million/cm2 as described elsewhere 
(Espe & Holen, 2013; Holen et al., 2014). Isolated cells were plated 
and grown in complete Leibovitz‐15 media (cL‐15), that is L‐15, added 
1% glutamax, 1% antibiotics and 10% calf serum (Espe & Holen, 
2013). In the pilot study, the media was supplemented with 1.0 mM 
or 10 mM metformin for 1 or 24 hr prior to OA treatment (0.2 and 
0.4 mM OA). The OA used was a water‐soluble OA from Sigma. All 
cells were harvested 24 hr post‐OA addition. In the main trial, the 
cells were pretreated with metformin at 1 mM and 10 mM for 24 hr 
before the OA was added and harvested 24 hr post‐OA supplemen‐
tation. In both trials, cells added only OA or metformin were included. 
In addition, a negative control grown in the cL‐15 media without ad‐
dition of OA or metformin was included. Plates were incubated in a 
dark normal atmosphere incubator at 9°C (Sanyo Incubator). Mean 
accumulation of lipid droplets and the expression of genes associ‐
ated with lipid metabolism and lipid transport were used to evaluate 
the concentrations and time necessary for the model to work. The 
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Cells were treated with metformin for 24 hr or not added any metformin before wells were added 
OA at either 0.2 or 0.4 mM. All cells were harvested 24 hr post addition of OA. A total of 9 wells (i.e. 
treatments) and cells isolated from five individual fish were sampled (n = 5).
TA B L E  1   The trial based on the pilot 
results used 0.2 or 0.4 mM oleic acid (OA) 
and 10 or 1 mM metformin following the 
design below
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2.3 | Harvesting of the cells
Monolayer liver cells without media were added 300 µl cold lysis 
buffer (CelLyticTM M cell lysis reagent, Sigma‐Aldrich) of which were 
added protease/phosphatase inhibitor cocktail 100× from Cell 
Signaling (BioNordica#5872) as described by the supplier. The super‐
natant from lysed cells was harvested after centrifugation (15 min 
at 10,000 g).	Supernatants	were	stored	at	−80°C	until	analysed	by	
Western blots. Likewise, monolayer liver cells without media were 
added 600 µl RLT Plus buffer (RNeasy® Plus Kit, Qiagen) as de‐
scribed by the supplier, homogenized using a syringe and frozen at 
−80°C	until	RNA	extraction.
2.4 | Gene expression analysis
RNA was extracted using RNeasy® Plus Kit (Qiagen) according 
to	 the	manufacturer's	 instructions	 and	 frozen	 at	 −80°C	 for	 fur‐
ther processing. The quantity and quality of RNA were tested 
using the NanoDrop Spectrophotometer and the RNA 6000 Nano 
LabChip® Kit (Agilent Technologies, Palo Alto, CA, USA) as de‐
scribed earlier (Espe et al., 2015; Holen et al., 2014). A two‐step 
real‐time quantitative polymerase chain reaction (RT‐qPCR) pro‐
tocol was used to measure the mRNA levels of the target genes in 
liver cells as described elsewhere (Espe et al., 2015; Holen et al., 
2014). The Ct values obtained were normalized using the geNorm 
tool as described (Olsvik, Lie, Jordal, Nilsen, & Hordvik, 2005) and 
presented as mean normalized gene expression (NGE). EGF1a and 
beta‐actin were used as reference genes. Genes involved in lipid 
synthesis, degradation and transport including some markers for 
inflammation were addressed (Holen et al., 2014). The primers 
used are shown in Supporting Information Table S1.
2.5 | Cells for Transition Emission Chromatography
Electron microscopy was used to evaluate structural changes in mi‐
tochondria and counting mean lipid droplets within liver cells follow‐
ing each treatment. Lipid droplets were counted in TEM pictures of 
20 different cells per treatment. Results are presented as mean num‐
ber of lipid droplets/cell. Transmission electron microscope (TEM, 
Jeol JEM‐1230, Molecular Imaging Center, University of Bergen) was 
used to image the cells.
2.6 | Western blot
Western blots were run as described previously (Espe & Holen, 2013) 
with modifications published elsewhere (Espe et al., 2015). In short, 
samples were mixed with Laemmli buffer (1:1) and run on precast 
10% SDS gels using a Bio‐Rad Mini‐PROTEAN® Cell. Thereafter, 
the proteins were blotted on polyvinylidene difluoride (PVDF) 
membranes, blocked and incubated overnight with the respective 
antibodies tested (1:1,000). The following primary rabbit antibod‐
ies from Cell Signaling Technology (BioNordika, Oslo, Norway) 
were used: P‐AMPKα (#2531), AMPKα (#2532), P‐ACC (#11818) 
and ACC (#3662). Then, HRP‐linked anti‐rabbit IgG (Cell Signaling, 
#7074, 1:500) was used as the secondary antibody. Amersham ECL 
Advance™ Western Blotting Detection Kit (GE Healthcare and Chemi 
Chemiluminescence) and Image Capture (Syngene, Cambridge, UK) 
were used to detect the proteins. Results are reported as abundance 
of proteins normalized against actin (Cell Signaling # 4970) and 
shown relative to the negative control.
2.7 | Statistical analysis
Differences in normalized gene expression (NGE) between treatment 
means were analysed by ANOVA followed by Tukey's post hoc test. 
p‐values < 0.05 were accepted statistically different. When the data did 
not fulfil the assumptions for normality and homogeneity in variance, 
the non‐parametric Kruskal–Wallis test was used. Western blot data 
and mean number of lipid droplets per cell were analysed using Dunett 
test (p < 0.05). Values are reported as the means ± standard error (SE, 
6 or 5 individual fish, the pilot and trial, respectively) with exception of 
Western blot analyses that were analysed in three fish per treatment.
3  | RESULTS
3.1 | Determination of time and concentration 
necessary to develop the model
First, a regression using metformin concentration ranging from 0.1 mM 
to 40 mM was run with the aim of testing what concentration of met‐
formin the primary liver cells tolerated. Exceeding 10 mM metformin did 
not give any change in gene expression of the tested gene (Supporting 
Information Figure S2 showing manganese superoxide dismutase, 
MnSOD). A pilot study using OA and metformin at different concentra‐
tions and times of metformin pretreatment was run to address the time 
of pretreatment necessary to affect gene expression in the liver cells of 
salmon. The concentrations and times tested are outlined in Supporting 
Information Figure S2. The pilot model with 1 hr pretreatment with 
metformin (1 mM) followed by 24‐hr OA treatment (0.2 mM) did not 
result in any change in gene expression of genes associated with lipid 
metabolism as compared to the control. Here, it is shown peroxisome 
proliferator‐activated receptor alpha (PPARa, Supporting Information 
Figure S3a) and acetyl CoA carboxylase (ACC, Supporting Information 
Figure S3b). Increasing the pretreatment time of metformin from 1 to 
24 hr prior to the OA supplementation did not result in any difference 
in the gene expression either. However, at 24 hr and 10 mM metformin 
affects the gene expression of (PPARa), while OA concentration at the 
double of the rodent model (0.4 mM) did not affect PPARa, but affect 
the gene expression of ACC. This was also the case of several other 
tested genes (not shown). It was evident that pretreatment with met‐
formin for a longer period than 1 hr was necessary to affect gene ex‐
pression. The experiment therefore used 24 hr pretreatment with 1.0 
or 10 mM metformin, followed by 0.2 or 0.4 mM OA treatment. Cells 
were harvested 24 hr post‐OA addition. Controls not added anything 
as well as controls added only OA or only metformin were included. 
Table 1 shows the arrangement of the wells used in the trial.
740  |     ESPE Et al.
0.2 mM OA
1 mM metformin + 0.2 mM OA




































































































F I G U R E  1
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3.2 | The development the fatty liver model and 
possibly preventive effect of TAG accumulation 
by metformin
Cells grown in 0.4 mM OA had significantly more (p < 0.0001) 
lipid droplets in the liver cells as compared to the negative control 
(Figure 1a). Even though the number of lipid droplets also increased 
in cells grown in 0.2 mM OA, they were not significantly different 
from the control cells. Pretreatment with metformin prior to OA 
supplementation prevented the accumulation of lipid droplets at 
both concentrations tested. However, the TEM pictures showed 
that cells grown in 10 mM metformin seem to have degraded mi‐
tochondria (Figure 1b). Metformin increased phosphorylation and 
thus activation of adenosine monophosphate‐activated protein 
kinase (AMPK) in a dose‐dependent manner (p = 0.041, Figure 2). 
Treatment with the higher metformin concentration (10 mM) prior to 
OA treatment at 0.4 mM tended to increase the amount of P‐AMPK, 
but not significantly. Phosphorylation and thus inactivation of ACC 
were not affected by treatments (p = 0.32, not shown). Neither were 
the respective unphosphorylated proteins affected by treatments 
(p = 0.51 and p = 0.54 for AMPK and ACC, respectively, not shown).
Cells pretreated with 10 mM metformin had higher gene ex‐
pression of PPARa when treated with OA at both 0.2 and 0.4 mM 
(Figure 3a, p < 0.0001 OA versus metformin pretreatment +OA), while 
cells grown in 1 mM metformin did not affect the PPARa gene expres‐
sion. Cells grown without pretreatment with metformin, but added OA 
did not differ from cells grown in the cL‐15 media (the control group). 
Likewise, the gene expression of the cluster of differentiation 36 (CD36) 
increased in cells grown in 10 mM metformin (Figure 3b, p < 0.0001). 
Cells pretreated with 10 mM metformin before OA supplementation 
increased CD36 expression. The gene expression of Apolipoprotein 
B100 (ApoB100) was similar to CD36 as 10 mM metformin pretreat‐
ment increased its expression independent of adding OA at 0.2 or 
0.4 mM (Figure 3c, p = 0.0006). Gene expression of ACC was similar 
to ApoB100 and CD36 as 10 mM metformin pretreatment prior to OA 
supplementation increased its gene expression (Figure 3d, p = 0.02).
On the other hand, both 1 and 10 mM metformin reduced the 
gene expression of liver x receptor (LXR) and this reduced gene expres‐
sion also persisted after OA treatments at both 0.2 and 0.4 mM OA 
(Figure 3e, p < 0.0001). Gene expression of sterol regulatory element‐
binding protein 2 (SREBP2) showed the same trend as LXR expression in 
that metformin decreased its gene expression (Figure 3f, p < 0.0001) at 
both 1 and 10 mM. The gene expression of carnitine palmitoyltransfer‐
ase 1 (CPT‐1) followed the same pattern as LXR (Figure 3g, p < 0.0001). 
Treatment with either 0.2 or 0.4 mM OA had no effect on gene expres‐
sion as compared to the control cells grown in the cL‐15 media. The 
gene expression of caspase‐3, acetyl CoA oxidase (ACO), PPARg and fatty 
acid synthase (FAS) was unaffected by treatments (not shown).
Liver cells treated with OA tended to have higher expression 
of the pro‐inflammatory interleukin‐8 (IL‐8) at both 0.2 and 0.4 mM 
OA, but IL‐8 expression only differed significantly from control 
cells treated with 10 mM metformin (Figure 4, p = 0.0005). Treating 
cells with metformin prior to the OA treatment generally decreased 
the gene expression of IL‐8, but did not reach a statistical differ‐
ence. The gene expression of the pro‐inflammatory interleukin‐1b 
and interleukin‐6 (IL‐1b and IL‐6) was too low to be calculated.
4  | DISCUSSION
Metformin reduces accumulated liver lipids (Kim et al., 2016; Liu et 
al., 2014; Malin & Kashyap, 2014), but is mainly used to treat TAG 
F I G U R E  1    The mean number of lipid droplets following 
the different treatments. Droplets were counted in 20 cells per 
treatment from TEM pictures (a). Cells grown in 0.4 mM oleic acid 
(OA) contained significantly more lipid droplets than the other 
treatments (p < 0.0001, Dunett). Values are mean lipid droplets per 
cell ± SE. The respective TEM from each treatment is shown (b). 
Arrows show lipid droplets. Cells treated with 10 mM metformin 
started to degrade the mitochondria as compared to cells treated 
with 1 mM metformin
1 mM metformin + 0.4 mM OA
10 mM metformin + 0.4 mM OA
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accumulation associated with diabetes and not to prevent lipid ac‐
cumulation in humans (He et al., 2009). The current trial did not use 
metformin to reduce and cure the fatty liver. Metformin was used to 
test whether metformin had the possibility to prevent TAG accumu‐
lation, which is more relevant for fish nutrition as deficiency of nu‐
trients increases TAG accumulation and liver size (Espe et al., 2010; 
Skjærven et al., 2018). The establishment of a fatty liver model using 
OA in primary liver cells isolated from Atlantic salmon succeeded. 
Addition of 0.4 mM OA increased the mean number of lipid droplets 
in the liver cells, while 0.2 mM OA did not differ from the control 
cells (Figure 1a). Our findings are in line with Liu et al. (2014) who 
reported that primary hepatocytes isolated from mice treated with 
OA (0.2 mM and 18 hr) accumulated TAG, while cells grown in media 
pretreated with metformin (0.5 mM and 12 hr) prior to OA treatment 
reduced their TAG content within the cells. Opposite to the rodent 
models (Liu et al., 2014), fish cells needed longer pretreatment time 
with metformin prior to OA treatment to prevent lipid accumula‐
tion within the liver cells. Likewise, Moracova et al. (2015) increased 
OA from 0.1 to 2.0 mM in primary hepatocytes isolated from rats, 
which resulted in a dose‐dependent increase in TAG accumulations. 
These results also are in line with the current study, but HepG2 cells 
needed 0.25 mM OA to induce lipid accumulation (Lian et al., 2011), 
which is less than the 0.4 mM needed by the salmon cells. Lately, 
also Zhou et al. (2019) used 0.4 mM OA and 0.2 mM metformin in 
liver cells isolated from blunt snout bream and found that metformin 
upregulated AMPK and attenuated lipid accumulation in high‐fat‐fed 
cells. Thus, salmon liver cells responded as the rodent model towards 
OA treatment, but needed higher concentration of OA as compared 
to the mammalian models as well as longer pretreatment time with 
metformin to attenuate the OA‐induced TAG accumulation. These 
differences are probably due to the fact that salmon is a cold‐water 
species and cells were incubated at lower temperatures than those 
commonly used for mammalian cells.
As in the mammalian models, metformin administration phos‐
phorylated and activated AMPK, while phosphorylation and inacti‐
vation of ACC did not occur. This is opposite to the results reported 
by Tokubuchi et al., (2017) who reported an increase in both P‐ACC 
and P‐AMPK following OA treatment. Activation of AMPK by phos‐
phorylation promotes ATP‐producing pathways as glycolysis, fatty 
acid oxidation and mitochondrial biogenesis, concomitantly inhibit‐
ing ATP‐consuming pathways as glucogenesis, glycogen synthesis, 
fatty acid synthesis and protein synthesis (Wong, Quinn, & Brown, 
2006). In addition, AMPK activation inactivates ACC and activates 
malonyl‐CoA carboxylase, thereby decreasing fatty acid and cho‐
lesterol synthesis (Choi et al., 2007; Mazza et al., 2012; Wong et 
al., 2006). Furthermore, activation of AMPK is known to activate 
PGC1a, the main mitochondrial biogenesis sensor mirroring mi‐
tochondrial DNA quality and maintenance (Barbieri et al., 2016). 
F I G U R E  2    As in mammalian models, 
metformin phosphorylated and activated 
AMPK (i.e. treatments 1–3; p = 0.041). 
Even though P‐AMPK also increased 
following 0.4 mM OA and metformin, the 
differences were not statistically different 
from the control. Activation of AMPK was 
normalized towards actin and calculated 
relative to the control group (Dunett, 
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Acetyl CoA carboxylase is a key regulator of mitochondrial fatty acid 
oxidation and is involved in regulating both oxidation and synthesis 
of fatty acids depending on being phosphorylated or not. P‐ACC is 
inactivated, and less malonyl‐CoA is produced. Low malonyl‐CoA 
thus reduces the fatty acid synthesis and increases the fatty acid 
oxidation (Song et al., 2015). The present trial could not report in‐
activation of ACC in salmon, probably due to relative high variations 
between the analysed fish. However, unphosphorylated ACC might 
act opposite to P‐ACC reducing oxidation of fat in line with the 
reduced gene expression of CPT‐1 indicating a reduced fat oxidation 
in the current trial. Inactivation of fatty acid oxidation in the pro‐
posed model following metformin pretreatment was not expected. 
Therefore, more studies testing which protein is activated or not are 
needed to unravel which proteins are present.
The effects observed in expression of genes affecting lipid me‐
tabolism were due to metformin, and minor effects of OA treatments 
were present in the current trial. Woo et al. (2014) reported that gene 
expression in cells isolated from obese mice showed reduced gene 
F I G U R E  3    Metformin increased gene expression of PPARa (a), CD36 (b), ApoB100 (c) and ACC (d) and attenuated gene expression of LXR 
(e), SREBP2 (f) and CPT‐1 (g). All values are means ± SEM, n = 5 (ANOVA, Tukey p < 0.05). 10 mM metformin generally resulted in higher or 
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expression of ACC, FAS and CPT‐1 in cells pretreated with 0.5 mM 
metformin prior to treatment with 0.25 mM palm oil. Metformin also 
increased the gene expression of PGC1a as well as the diameter of 
the adipocytes (Aatsinki et al., 2014). PGC1a is a master regulator 
of oxidative phosphorylation as well as mitochondrial biogenesis. 
Increased gene expression of PGC1a also increases the expression 
of PPARa also improving the mitochondrial fatty acid oxidation, 
while any increased bile acids will suppress PGC1a through LXR. The 
present study did not find any differences in PGC1a expression, but 
PPARa and ACC both increased following metformin administration, 
which indicates a possible higher oxidation of lipid in these cells. One 
should expect increased expression of CPT‐1 following metformin 
pretreatment, but in the current trial expression of CPT‐1 was re‐
duced in metformin‐pretreated cells, while FAS and ACO were un‐
affected by treatment. The reduced expression of CPT‐1 decreased 
following metformin pretreatment, and no effects on ACO and FAS 
were unexpected. Zhou et al. (2019) reported that the gene expres‐
sion of PPARa, CPT‐1 and PGC1a all was upregulated following met‐
formin treatment in liver cells isolated from blunt snout bream. The 
reason we did not find increased CPT‐1 expression in salmon liver 
following metformin needs to be investigated in more detail. In the 
rodent model, CPT‐1 expression generally increased following treat‐
ment with metformin (Tokubuchi et al., 2017). It should be noted 
that CPT‐1 expression was not significantly affected by treatment 
in the pilot study. Metformin pretreatment at 10 mM significantly 
increased the transcription of PPARa, which is well known for regu‐
lating and increasing several genes in lipid metabolism and increasing 
several genes related to lipid oxidation. The increase in PPARa by 
10 mM metformin was independent of the added concentration of 
OA, while cells grown in either 1 mM metformin or in OA did not 
differ from the controls. This is in line with a previous study involving 
rainbow trout hepatocytes where an increase in PPARa following OA 
(1 mM) treatment was reported (Woo et al., 2014).
ApoB100 is necessary for assembly of VLDL and exports of lipids 
from the liver (Vance, Walkey, & Cui, 1997; Watkins, Zhu, & Zeisel, 
2003). In the current trial, gene expression of ApoB100 was signifi‐
cantly higher following pretreatment with metformin especially at 
the 10 mM concentration. Depletion of CD36 reduced VLDL secre‐
tion from liver in mice (Nassir, Adewole, Brunt, & Abumrad, 2013). 
In the current study, pretreatment with metformin increased the 
CD36 gene expression indicating a possible increased secretion of 
VLDL contributing to the reduced amount of lipid droplet observed 
in these groups. Probably, both ApoB100 and CD36 participated in 
increased export of lipids from the liver cells leading to the low lipid 
phenotype observed in the current trial. The metformin concentra‐
tion needed to prevent lipid accumulation in Atlantic salmon cells 
should be followed up using lower metformin concentrations than 
10 mM. Especially as the TEM pictures indicated that 10 mM might 
have been too high as the mitochondria seem degraded.
SREBP‐2 is known to upregulate genes involved in biosynthesis of 
cholesterol and its uptake, while LXR is a cholesterol sensor known 
to upregulate cholesterol efflux genes (Wong et al., 2006). Both 
SREBP2 and LXR gene expression were significantly downregulated 
following the addition of metformin in hepatocytes from salmon, in‐
dicating that metformin administration reduced cholesterol synthe‐
sis and its efflux from the hepatocytes. This is in line with previous 
studies on metformin treatment of obese children with metabolic 
syndrome, where metformin treatment reduced circulating choles‐
terol (Luong, Oster, & Ashraf, 2015). AMPK activation, as is present 
following metformin administration in the current trial, was reported 
to suppress LXR expression and reducing lipid accumulation in 
HepG2 cells (Lee et al., 2015). As P‐AMPK was higher following met‐
formin treatment in the current trial (i.e. cells incubated in 10 mM), 
this might have influenced the expression of LXR expression.
The increased transcription of the cytokine IL‐8 after OA addi‐
tion indicates a pro‐inflammatory response to the free fatty acid 
supplementation, while the addition of metformin at the higher 
concentration (10 mM) prevented this response. High concentra‐
tion of free fatty acids is toxic to the liver cells, and some of this 
toxicity is expressed through increased inflammatory response 
(Feldstein et al., 2004; Yao et al., 2011). The reduced transcrip‐
tion of cytokines following metformin pretreatment is in line with 
results reported by Aatsinki et al. (2014); Arai et al. (2010), who 
found reduced expression of IL‐1b and IL‐6 following metformin 
treatment. The present study analysed both IL‐1b and IL‐6 together 
with IL‐8. However, only IL‐8 is reported due to the very low gene 
expression of IL‐1b and IL‐6. The lower gene expression of IL‐8 fol‐
lowing metformin treatment at both 1 and 10 mM indicated that 
metformin might have an anti‐inflammatory function also in the 
salmon liver cells. This is in line with a report (Simon‐Szabó et al., 
F I G U R E  4    Addition of oleic acid (OA) increased the gene 
expression of IL‐8 at both 0.2 and 0.4 mM compared to cells grown 
in the respective controls (p = 0.002, ANOVA followed by Tukey, 
p < 0.05), indicating that OA promotes inflammation in primary liver 
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2014) where it was observed that metformin influences pro‐in‐
flammatory cytokines and reduced active cleaved caspase‐3 thus 
improving viability of the cells. The active cleaved caspase‐3 was 
not analysed in the present study, only its gene expression of 
which did not change upon treatments; thus, it is not possible to 
conclude whether cell viability was affected in the current study.
5  | CONCLUSION
The present study succeeded in building a model of the fatty liver in 
primary liver cells isolated from Atlantic salmon. The model in question 
seems to be pretty much like the mammalian, though requiring higher 
concentration of OA. Metformin treatment probably reduced liver lipid 
accumulation by increasing PPARa, ACC and transport of lipids out of 
the hepatocytes (ApoB100 and CD36). In addition, OA supplementation 
without any metformin pretreatment increased the gene expression of 
IL‐8 compared to cells treated with 10 mM metformin, probably affect‐
ing inflammation. To prevent accumulation of lipid droplets in liver cells 
of Atlantic salmon, higher concentration of metformin and longer treat‐
ment time are required than the proposed mammalian model.
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